Clot-Busting Drugs: Unlocking Life-Saving Interventions in Thrombosis Care Introduction: Fighting Time in Stroke and Cardiac Events Clot-busting drugs, or thrombolytics, are pharmacological agents used to dissolve blood clots in acute medical emergencies like myocardial infarction, ischemic stroke, and pulmonary embolism. These medications improve survival and reduce long-term disability if administered quickly. https://www.marketresearchfuture.com/reports/clot-busting-drugs-market-31405 Mechanism of Action and Drug Types Alteplase (tPA): FDA-approved for stroke within 3–4.5 hours Reteplase and Tenecteplase: Used in acute MI Urokinase: Approved for pulmonary embolism Regulatory Guidelines FDA and EMA guidelines stipulate time-dependent administration Stroke guidelines by AHA/ASA dictate inclusion/exclusion criteria WHO Essential Medicines List includes several thrombolytics Challenges and Advancements Risk of hemorrhage necessitates careful patient selection AI-supported imaging helps determine eligibility faster Next-gen fibrinolytics aim to reduce bleeding complications Conclusion Clot-busting drugs remain central to emergency medicine. With evolving clinical protocols and regulatory clarity, these therapies save lives and restore function in time-critical conditions.